Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Adagrasib Shows Impressive Activity in KRAS G12C–Mutant CRC

September 19th 2021

Adagrasib alone or in combination with cetuximab elicited encouraging antitumor activity and safety in heavily pretreated patients with KRAS G12C–mutant colorectal cancer, according to findings from the phase 1/2 KRYSTAL-1 trial.

Cabozantinib Demonstrates Real-World OS Benefit in Second-Line RCC

September 18th 2021

Cabozantinib as a second-line treatment showed improved overall survival outcomes compared with second-line axitinib in patients with advanced renal cell carcinoma.

Trastuzumab Deruxtecan Elicits Encouraging Activity in Western Patients With HER2+ Gastric/GEJ Cancer

September 17th 2021

Fam-trastuzumab deruxtecan-nxki as a second-line treatment elicited a 38% confirmed objective response rate in Western patients with HER2-positive gastric/gastroesophageal junction cancer.

Nivolumab/Ipilimumab Demonstrates Superior Likelihood of Long-Term Survival Vs Sunitinib in Advanced RCC

September 17th 2021

Efficacy outcomes were superior with nivolumab plus ipilimumab compared with sunitinib in patients with advanced renal cell carcinoma.

Toripalimab/Chemo Combo Elicits Survival Benefit in Frontline Esophageal Squamous Cell Carcinoma

September 17th 2021

The addition of toripalimab to platinum-based chemotherapy demonstrated significantly improved survival outcomes in patients with advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 expression.

Sintilimab Improves OS in Advanced ESCC, Gastric/GEJ Cancer

September 17th 2021

Findings from a pair of studies presented at the 2021 European Society for Medical Oncology Annual Meeting showed that adding sintilimab to chemotherapy significantly improved overall survival compared with chemotherapy alone in patients with unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma and those with unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma.

Nivolumab/Cabozantinib Combo Yields Efficacy Regardless of Prior Nephrectomy in RCC

September 17th 2021

Nivolumab and cabozantinib demonstrated significant benefits in progression-free survival and objective response rate for patients with renal cell carcinoma regardless of whether they had a prior nephrectomy.

Nivolumab/Chemo Approaches EU Approval for Select HER2– Advanced or Metastatic Gastric, GEJ, or Esophageal Adenocarcinoma

September 17th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab plus fluoropyrimidine and platinum-containing chemotherapy as frontline treatment for adult patients with HER2-negative advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma with a PD-L1 combined positive score of 5 or higher.

HCC: IO in Liver Transplant Recipients

September 17th 2021

A debate regarding the appropriateness of immunotherapy following liver transplantation in patients with hepatocellular carcinoma.

The LEGACY Study in HCC

September 17th 2021

Implications on treatment practices of the LEGACY study of Y-90 glass microspheres in patients with unresectable solitary hepatocellular carcinoma.

Linagliptin/Atezolizumab Combo Shows Limited Clinical Activity in Second-Line Gastric/GEJ Cancer

September 16th 2021

Linagliptin plus atezolizumab was linked with limited responses as a second-line treatment for patients with locally advanced or metastatic gastric or gastroesophageal junction cancer who participated in an arm of the open-label, phase 1b/2 MORPHEUS platform.

Promising Results Push Nivolumab/Chemotherapy Forward in Gastric Cancer

September 15th 2021

Jaffer A. Ajani, MD, unpacks the performance of nivolumab in combination with chemotherapy in some subgroups of gastric cancer.

Adjuvant Pembrolizumab Continues to Uphold DFS Benefit Across RCC Subgroups

September 14th 2021

Pembrolizumab as an adjuvant therapy compared with placebo continued to showcase an impressive disease-free survival benefit in patients with clear cell renal cell carcinoma following nephrectomy, with improvement observed across subgroups.

Dismutase Mimetic/SBRT Continues to Impress in Locally Advanced Pancreatic Cancer

September 14th 2021

The dismutase mimetic avasopasem manganese was found to improve overall survival, progression-free survival, local disease control, time to metastases, and tumor response rate compared with placebo in patients with unresectable or borderline resectable locally advanced pancreatic cancer who were undergoing stereotactic body radiation.

FDA Accepts BLA for Tislelizumab in Esophageal Squamous Cell Carcinoma

September 13th 2021

The FDA has accepted for review a biologics license application for tislelizumab as a potential therapeutic option in patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma following previous systemic therapy.

Loaiza-Bonilla Offers Guidance on Optimizing Treatment Selection in Pancreatic Cancer

September 13th 2021

Dr. Loaiza-Bonilla discusses approaches to frontline treatment selection in metastatic pancreatic cancer, the effects of adverse effects and toxicities in treatment planning, and treatment options available to patients post gemcitabine-based regimens.

Nivolumab Plus Ipilimumab Response Signals Change for Cytoreductive Nephrectomy in Advanced RCC

September 11th 2021

Primary tumor response to nivolumab plus ipilimumab observed results of a Japanese study indicates a changing role for the timing of cytoreductive nephrectomy for patients with advanced renal cell carcinoma.fr

Selecting First-Line Therapy for Advanced HCC

September 10th 2021

An overview of factors that deem patients appropriate for atezolizumab/bevacizumab vs lenvatinib or sorafenib as frontline therapy for advanced hepatocellular carcinoma.

Frontline IO for Advanced HCC

September 10th 2021

Considerations regarding the use of nivolumab as frontline treatment for advanced hepatocellular carcinoma.

Pembrolizumab Approved in China for Frontline Advanced Esophageal or GEJ Cancer

September 7th 2021

The National Medical Products Administration in China has approved pembrolizumab for use in combination with platinum- and fluoropyrimidine-based chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic esophageal carcinoma or gastroesophageal junction cancer.